Among all epitopes tested, we were not able to identify novel antigen-specificities (>0.15%) both in tumours or in the peripheral circulation of anti-CTLA-4-treated mice that were not also seen in isotype mAb-treated mice. Here, CTLA4 is linked to neoplasm.